Last reviewed · How we verify
NCT06357858
ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck
Phase 1 trial testing INQOVI (decitabine and cedazuridine) in Recurrent Squamous Cell Carcinoma of the Head and Neck. Withdrawn.
28 February 2025
Quick facts
| Lead sponsor | Case Comprehensive Cancer Center |
|---|---|
| Phase | Phase 1 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 1 June 2024 |
| Primary completion | 28 February 2025 |
| Estimated completion | 28 February 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- INQOVI (decitabine and cedazuridine) — full drug profile →
- Nivolumab (nivolumab) — full drug profile →
Conditions studied
- Recurrent Squamous Cell Carcinoma of the Head and Neck — all drugs for Recurrent Squamous Cell Carcinoma of the Head and Neck →
- Metastatic Squamous Cell Carcinoma — all drugs for Metastatic Squamous Cell Carcinoma →
- Head and Neck Squamous Cell Carcinoma — all drugs for Head and Neck Squamous Cell Carcinoma →
Sponsor
Case Comprehensive Cancer Center — full company profile →
Who can join
19 and older, any sex, with Recurrent Squamous Cell Carcinoma of the Head and Neck or Metastatic Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to see if the combination of experimental drug ASTX727 and Nivolumab enhances the antitumor immune response in participants will recurrent or metastatic squamous cell carcinoma of the head and neck. Participants will take a pill called ASTX727 for 4 or 5 days every month followed by an injection of Nivolumab one week after the first dose of study medication.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06357858
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Case Comprehensive Cancer Center trials
Trials by the same sponsor.
- NCT06811454 — Mindfulness-based Intervention for Depressive Symptoms Sent Via Text (MINDSET) · NA · not yet recruiting
- NCT07167056 — Artificial Intelligence-Powered Support For Quality Of Life Improvement In Participants With Cancer · NA · recruiting
- NCT07084779 — Investigation of Impact of AI on Prostate Cancer Workflow · NA · recruiting
- NCT06904482 — Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood · Phase 2 · recruiting
- NCT07044362 — Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06357858 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Case Comprehensive Cancer Center
- Last refreshed: 3 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06357858.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing